5 reasons to buy CSL Limited shares

Shares of CSL Limited (ASX:CSL) are approaching $115 a share and don't look like stopping.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares of CSL Limited (ASX: CSL) have once again resumed their long history of outperforming the broader market and are now fetching a record price of close to $115 per share.

The biopharmaceutical giant is one of the true Australian success stories and has both the reputation, and geographic reach, to compete on a global scale.

Not only does the company provide products that help the lives of millions of people, CSL has also delivered exceptional returns for shareholders. In fact, it has been one of the best-performing stocks on the ASX over the past 10 years having delivered, on average, a total shareholder return of 23.1% each year.

Although investors often complain that the shares are too expensive or the dividend yield is too low, this has not stopped the shares from continuing to make new record highs over a very long period of time.

Here are just five reasons why I think investors are willing to pay a premium for CSL shares:

  • Consistent Earnings Per Share (EPS) Growth – Ultimately, CSL's increasing share price has reflected the company's ability to consistently increase its EPS.  As the simple graph below demonstrates, CSL has nearly doubled its EPS over the past five years.
    Source: CSL Presentation
    Source: CSL Presentation

    Even more impressively perhaps, is the fact that CSL has been able to quadruple its EPS over the past 10 years. It is unsurprising, therefore, to see the rapid increase in the share price during that time.

    Investors should also note that the company has undertaken a number of share buy-backs which has reduced the number of shares on issue by around 27%. This has also been a driving force behind increasing the company's EPS and a $1 billion buy-back is currently underway.

  • Geographic Diversification – CSL's operations are not limited to Australia and this presents huge growth opportunities for the company.
    Source: CSL Presentation
    Source: CSL Presentation

    As the slide above shows, CSL already has a strong presence in the North American market and this is the most lucrative healthcare market in the world. The company also has a growing presence in Asia and Europe.

  • Lower Australian dollar tailwind – Even without the help of a falling Australian dollar, CSL has still been able to deliver both sales and earnings growth in constant currency terms. With that said, the company reports its earnings and dividends in US dollars so the recent fall of the Australian dollar has been a tailwind for Australian investors.
  • Product Diversification – Unlike other biopharmaceutical companies, CSL has a broad range of treatments in a number of different disease categories.
Source: CSL Presentation
Source: CSL Presentation

In my opinion, this makes CSL a far less risky investment proposition than other companies that operate in the same market. Importantly, CSL has a number of significant products that are due to be launched over the next 12 months and these products are expected to accelerate earnings growth from FY17 and beyond.

  • Increasing return on equity (ROE) – CSL has typically paid out less than 40% of its profits to shareholders as dividends and this has actually benefited shareholders in the long term. Instead of paying out higher dividends, the company has been able to reinvest those funds and generate a significantly higher return on those funds than could otherwise have been achieved. It has been able to do this year after year and this has seen CSL's return on equity increase from 25% in 2010 to 49% in 2015.

Foolish takeaway

I think investors are likely to remain strong supporters of CSL even though it currently trades at a price-to-earnings ratio of around 30.

The company has an impressive pipeline of new treatments and a track record that is second to none. While some investors may find it difficult to comprehend CSL's current valuation, I would not be surprised to see the shares trade significantly higher over the coming years.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »